<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01144728</url>
  </required_header>
  <id_info>
    <org_study_id>GLMET_L_04718</org_study_id>
    <secondary_id>U1111-1116-9956</secondary_id>
    <nct_id>NCT01144728</nct_id>
  </id_info>
  <brief_title>Initiation and Titration of Amaryl</brief_title>
  <acronym>AMIT KZ</acronym>
  <official_title>AMIT Study - Amaryl M Initiation and Titration Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:

        -  To describe the conditions of initiation and titration of Amaryl M, according to
           previous treatment:

        -  initial dose

        -  titration scheme

        -  efficacy after 4 months assessed by HbA1C

        -  tolerability (number and severity of hypoglycaemia)

      Secondary Objective:

        -  Fasting Plasma Glucose

        -  Weight evolution
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycolysated Haemoglobin (HbA1c)</measure>
    <time_frame>From baseline to Month 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients With Glycosylated Haemoglobin (HbA1c) Value &lt; 7%</measure>
    <time_frame>Month 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evolution of Fasting Plasma Glucose (FPG)</measure>
    <time_frame>From baseline to Months 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post Prandial Plasma Glucose (PPPG)</measure>
    <time_frame>Month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients for each start dose</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with different final doses</measure>
    <time_frame>Month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Symptomatic Hypoglycemia</measure>
    <time_frame>During treatment period (4 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>Month 4</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Single arm Glimepiride+metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start and titration based on FBG and tolerance. Titration should be achieved within maximum 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLIMEPIRIDE + METFORMIN</intervention_name>
    <description>Pharmaceutical form: Tablet Route of administration: oral Dose regimen : fixed dose combination of glimepiride / metformin: 1/250, 2/500</description>
    <arm_group_label>Single arm Glimepiride+metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with Type 2 diabetes who have been treated with a stable dose (any dose) of :

          -  sulfonylurea monotherapy or

          -  metformin monotherapy or

          -  free combination of glimepiride and metformin with a stable dose (any dose)

          -  Body Mass Index (BMI) between 20 and 40 kg/m2

          -  HbA1c superior or egal to 7.5%

          -  FPG superior or egal 7 mmol/l

        Exclusion criteria:

          -  Secondary or insulin-dependant diabetes

          -  Any severe chronic disease (hepatic, renal impairments)

          -  History of major cardiovascular event in the last 6 months

          -  Acute conditions with the potential to alter renal function such as: dehydratation,
             severe infection, shock, IV administration of iodinated contrast agents

          -  Allergy to sulfonylurea, metformin

          -  Drug or alcohol abuse

          -  Pregnancy, lactation

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Almaty</city>
        <country>Kazakhstan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kazakhstan</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2010</study_first_submitted>
  <study_first_submitted_qc>June 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2010</study_first_posted>
  <last_update_submitted>January 28, 2011</last_update_submitted>
  <last_update_submitted_qc>January 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2011</last_update_posted>
  <responsible_party>
    <name_title>Trial Transparency Team</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

